Hookipa Sale Purchase Of Stock from 2010 to 2024

HOOK Stock  USD 2.52  0.04  1.61%   
Hookipa Pharma Sale Purchase Of Stock yearly trend continues to be quite stable with very little volatility. The value of Sale Purchase Of Stock is projected to decrease to about 60.2 M. From the period between 2010 and 2024, Hookipa Pharma, Sale Purchase Of Stock regression line of its data series had standard deviation of  27,091,518 and standard deviation of  27,091,518. View All Fundamentals
 
Sale Purchase Of Stock  
First Reported
2010-12-31
Previous Quarter
86.6 M
Current Value
60.2 M
Quarterly Volatility
27.1 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Hookipa Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Hookipa Pharma's main balance sheet or income statement drivers, such as Tax Provision of 454.6 K, Net Interest Income of 4.8 M or Interest Income of 5.2 M, as well as many indicators such as Price To Sales Ratio of 3.61, Dividend Yield of 0.0 or PTB Ratio of 0.81. Hookipa financial statements analysis is a perfect complement when working with Hookipa Pharma Valuation or Volatility modules.
  
Check out the analysis of Hookipa Pharma Correlation against competitors.
For more information on how to buy Hookipa Stock please use our How to buy in Hookipa Stock guide.

Latest Hookipa Pharma's Sale Purchase Of Stock Growth Pattern

Below is the plot of the Sale Purchase Of Stock of Hookipa Pharma over the last few years. It is Hookipa Pharma's Sale Purchase Of Stock historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Hookipa Pharma's overall financial position and show how it may be relating to other accounts over time.
Sale Purchase Of Stock10 Years Trend
Very volatile
   Sale Purchase Of Stock   
       Timeline  

Hookipa Sale Purchase Of Stock Regression Statistics

Arithmetic Mean59,161,747
Geometric Mean38,745,735
Coefficient Of Variation45.79
Mean Deviation15,121,929
Median58,892,000
Standard Deviation27,091,518
Sample Variance734T
Range111.8M
R-Value0.07
Mean Square Error786.1T
R-Squared0.01
Significance0.79
Slope448,625
Total Sum of Squares10275.3T

Hookipa Sale Purchase Of Stock History

202460.2 M
202386.6 M
202275.3 M
2021203 K
202075.1 M
2019112 M
20186.9 M

About Hookipa Pharma Financial Statements

Hookipa Pharma investors utilize fundamental indicators, such as Sale Purchase Of Stock, to predict how Hookipa Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Sale Purchase Of Stock86.6 M60.2 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Hookipa Pharma is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Hookipa Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Hookipa Pharma Stock. Highlighted below are key reports to facilitate an investment decision about Hookipa Pharma Stock:
Check out the analysis of Hookipa Pharma Correlation against competitors.
For more information on how to buy Hookipa Stock please use our How to buy in Hookipa Stock guide.
You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Hookipa Pharma. If investors know Hookipa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Hookipa Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.67)
Revenue Per Share
4.403
Quarterly Revenue Growth
(0.52)
Return On Assets
(0.20)
Return On Equity
(0.49)
The market value of Hookipa Pharma is measured differently than its book value, which is the value of Hookipa that is recorded on the company's balance sheet. Investors also form their own opinion of Hookipa Pharma's value that differs from its market value or its book value, called intrinsic value, which is Hookipa Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Hookipa Pharma's market value can be influenced by many factors that don't directly affect Hookipa Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Hookipa Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Hookipa Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hookipa Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.